Market research
EPIX ESSA Pharma Inc
NASDAQ USD Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 10M
- P/E ratio
- Not available
- Analyst target
- 1.7443
- Dividend yield
- 87.%
- Beta
- 1.53
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA29668H7085
- Market cap
- 10M
- P/E ratio
- Not available
- Analyst target
- 1.7443
- Dividend yield
- 87.%
- Beta
- 1.53
About
About ESSA Pharma Inc
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. As of October 9, 2025, ESSA Pharma Inc. operates as a subsidiary of Alexis Bio, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EPIX discussion.
5 years, 4 months ago
ESSA Pharma Inc is currently in a long term uptrend where the price is trading 37.0% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
ESSA Pharma Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 41.2% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 17.3% to $-4M since the same quarter in the previous year.
Based on the above factors, ESSA Pharma Inc gets an overall score of 2/5.